Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient‐derived cancer cells
- 4 November 2018
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 144 (6) , 1356-1366
Abstract
Renal cell cancer (RCC) has become a prototype example of the extensive intratumor heterogeneity and clonal evolution of human cancers. However, there is little direct evidence on how the genetic heterogeneity impacts on drug response profiles of the cancer cells. Our goal was to determine how genomic clonal evolution impacts drug responses. Finding from our study could help to define the challenge that clonal evolution poses on cancer therapy. We established multiple patient‐derived cells (PDCs) from different tumor regions of four RCC patients, verified their clonal relationship to each other and to the uncultured tumor tissue by genome sequencing. Furthermore, comprehensive drug‐sensitivity testing with 460 oncological drugs was performed on all PDC clones. The PDCs retained many cancer‐specific copy number alterations and mutations in driver genes such as VHL, PBRM1, PIK3C2A, KMD5C and TSC2 genes. The drug testing highlighted vulnerability in the PDCs toward approved RCC drugs, such as the mTOR‐inhibitor temsirolimus, but also novel sensitivities were uncovered. The individual PDC clones from different tumor regions in a patient showed distinct drug–response profiles, suggesting that genomic heterogeneity contributes to the variability in drug responses. Studies of multiple PDCs from a patient with cancer are informative for elucidating cancer heterogeneity and for the determination on how the genomic evolution is manifested in cancer drug responsiveness. This approach could facilitate tailoring of drugs and drug combinations to individual patients.Keywords
This publication has 37 references indexed in Scilit:
- Integrated molecular analysis of clear-cell renal cell carcinomaNature Genetics, 2013
- A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell CarcinomaScience Translational Medicine, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial CellsThe American Journal of Pathology, 2012
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinomaNature, 2011
- Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatmentEuropean Journal of Cancer, 2010
- Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genesNature, 2010
- Review: Targeted therapy in renal cancerTherapeutic Advances in Medical Oncology, 2009
- Evaluation of the 3p21.3 tumour-suppressor gene clusterOncogene, 2007
- Primary cell cultures as models of prostate cancer developmentEndocrine-Related Cancer, 2005